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SYSTEMATIC REVIEW AND META-ANALYSIS

Association of Isolated Coronary
Microvascular Dysfunction With Mortality
and Major Adverse Cardiac Events: A
Systematic Review and Meta-Analysis of
Aggregate Data
Mark A. Gdowski, MD; Venkatesh L. Murthy, MD, PhD; Michelle Doering, MLS; Andrea G. Monroy-Gonzalez, MD;
Riemer Slart, MD, PhD; David L. Brown , MD
BACKGROUND: The impact of coronary microvascular dysfunction (CMD), as diagnosed by reduced coronary flow reserve, on
the outcomes of patients with symptoms of myocardial ischemia and nonobstructive coronary artery disease is poorly understood. We performed a systematic review and meta-analysis of observational studies to determine the association of CMD
with outcomes.
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METHODS AND RESULTS: We searched online databases for studies where coronary flow reserve was measured invasively or
noninvasively, clinical events were recorded after determination of coronary flow reserve, and the frequency of those events
was reported for patients with and without CMD. The primary outcome was all-cause mortality. The secondary outcome was
major adverse cardiac events, including cardiac or cardiovascular death, nonfatal myocardial infarction, cardiac hospitalization, or coronary revascularization. Estimates of effect were calculated from crude event rates with a random-effects model.
There were 122 deaths in the 4661 patients without CMD (2.6%) and 183 deaths in the 1970 patients with CMD (9.3%). The
odds ratio for mortality in patients with CMD compared with those without CMD was 3.93 (95% CI, 2.91–5.30; P<0.001). There
were 167 major adverse cardiac events in the 3742 patients without CMD (4.5%) and 245 events in the 1447 patients with CMD
(16.9%). The odds ratio for major adverse cardiac events in patients with CMD compared with those without CMD was 5.16
(95% CI, 2.81–9.47; P<0.001).
CONCLUSIONS: CMD is associated with a nearly 4-fold increase in mortality and a 5-fold increase in major adverse cardiac
events. Future studies are needed to identify effective strategies to diagnose and treat CMD.
Key Words: coronary flow reserve ■ coronary microvascular dysfunction ■ meta-analysis ■ outcomes

C

hest pain is among the most common symptoms evaluated in emergency departments and
outpatient clinical settings. Although the differential diagnosis is extensive, most evaluations of
adults with risk factors for cardiovascular disease
focus on the diagnosis of obstructive atherosclerosis of the epicardial coronary arteries, which is often

considered the leading cause of myocardial ischemia
and the primary driver of adverse outcomes. However,
patients presenting with chest pain and found not to
have obstructive coronary artery disease (CAD) on
coronary angiography are increasingly recognized.1–3
It is estimated that 3 to 4 million men and women
in the United States have symptoms of myocardial

Correspondence to: David L. Brown, MD, Cardiovascular Division, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8086, St.
Louis, MO 63110. E-mail: d.brown@wustl.edu
Supplementary Materials for this article are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.014954
For Sources of Funding and Disclosures, see page 9.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use
is non-commercial and no modifications or adaptations are made.
JAHA is available at: www.ahajournals.org/journal/jaha

J Am Heart Assoc. 2020;9:e014954. DOI: 10.1161/JAHA.119.0149541

Gdowski et al

Coronary Microvascular Dysfunction and Outcomes

CLINICAL PERSPECTIVE
What Is New?

• In this systematic review and meta-analysis
of >5000 patients with suspected ischemia,
nonobstructive epicardial coronary artery disease on coronary angiography, or absence of
myocardial ischemia on stress testing, ≈30%
of patients, equally divided between men and
women, had abnormally reduced coronary flow
reserve diagnostic of coronary microvascular
dysfunction.
• In these patients, we observed a nearly 4-fold
higher mortality and a 5-fold increase in major
adverse cardiac events among individuals with
coronary microvascular dysfunction compared
with those with normal coronary microvascular
function.

What Are the Clinical Implications?

• These results support the need to integrate the
totality of the coronary circulation, both macrovascular and microvascular, when conceptualizing the pathophysiological characteristics,
treatment, and prognosis of patients with symptoms of ischemic heart disease.

In the absence of obstructive CAD, CFR, the ratio of
coronary flow achieved at maximal coronary vasodilation/flow under baseline conditions, reflects coronary
microvascular function; an abnormally reduced CFR
indicates CMD.3 CFR can be measured invasively as
an adjunct to coronary angiography or noninvasively,
using positron emission tomography (PET) or transthoracic Doppler echocardiography of the left anterior
descending coronary artery.17
Patients presenting with angina and found not to
have obstructive CAD are often given reassurance
that their symptoms are noncardiac18 and do not place
them at an increased risk of adverse events. However,
these patients, if found to have CMD on the basis of
an abnormal CFR, have been shown in several single-
center studies to have increased rates of all-cause or
cardiac mortality and MACE. To better understand the
impact of isolated CMD on outcomes, we performed
a systematic review and meta-
analysis of published
studies to determine the association of CMD with mortality and MACE in type 1 patients without obstructive
CAD or other cardiac pathological characteristics.

METHODS
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The data that support the findings of this study are
available from the corresponding author on reasonable request.

Nonstandard Abbreviations and Acronyms
CFR
CMD
MACE
PET

coronary flow reserve
coronary microvascular dysfunction
major adverse cardiac event(s)
positron emission tomography

ischemia with no obstructive CAD.4,5 This population
of patients has an elevated risk of mortality and major
adverse cardiac events (MACE).2 One potential cause
of angina without obstructive CAD is coronary microvascular dysfunction (CMD), a disorder affecting the
structure and/or function of the coronary microcirculation, resulting in reduced coronary flow reserve
(CFR). CMD is associated with known cardiovascular risk factors, including hypertension,6,7 diabetes
mellitus,8–10 hypercholesteremia,11 and smoking.12–15
However, only ≈17% of variance in CFR is explained
by traditional risk factors and <1% is explained by
sex.16 Camici and Crea classified CMD into 4 main
types based on their different pathophysiological
characteristics: type 1, CMD in the absence of myocardial disease and obstructive CAD; type 2, CMD in
myocardial disease; type 3, CMD in obstructive CAD;
and type 4, iatrogenic CMD.3

Protocol and Registration
We conducted a systematic review and meta-analysis
of published studies, according to the Meta-A nalysis
of Observational Studies in Epidemiology guidelines.19 This study was registered at the International
Prospective Register of Systematic Reviews
(CRD42019117036).

Information Sources
The search was implemented in April 2019 by a
medical librarian (M.D.) in Ovid Medline 1946-
,
Embase.com 1947-
, Scopus 1960-
, Cochrane
Central Register of Controlled Trials, Database of
Abstracts of Reviews of Effects, Cochrane Database
of Systematic Reviews, and Clinicaltrials.gov using
controlled vocabulary and keywords for the following: coronary flow reserve, measurement, diagnostic
imaging, thermodilution, follow-
up, hospitalization,
MACE, and death. Articles were restricted to the
English language and published literature. The full
search strategy is provided in Data S1.

Study Eligibility
Studies were included in the meta-analysis if CFR
was prospectively measured either invasively or
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noninvasively; clinical events, including death, cardiovascular death, cardiac death, myocardial infarction,
hospital admission, and/or coronary revascularization, that occurred after determination of CFR were
recorded and the frequency of those events were
compared between patients with normal and abnormal CFR. The definition of abnormal CFR was that
used in each study and had to be defined prospectively. To limit the study population to isolated or type
1 CMD, only studies of patients with nonobstructive CAD on invasive coronary angiography (or who
had a negative stress test for myocardial ischemia if
coronary angiography was not performed) were included and studies of patients with a history of heart

transplantation, cardiomyopathy, or aortic stenosis
were excluded.

Study Selection
The study selection process is presented in Figure 1.
Two independent reviewers (M.A.G., D.L.B.) initially
screened the retrieved citations for potential relevance
by assessment of the title and abstract to determine
eligibility. The full text of the article was reviewed if the
content was not clear from the abstract. Agreement
was 100%. If a study was potentially relevant, the full
report was assessed using the selection criteria for inclusion. In cases where there was overlap of the study

6532 Total number of records
idenfied through database search

2919 Duplicates removed
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3613 Total number of
arcles screened

3543 Arcles excluded based on tle and
abstract

70 Full text arcles retrieved for
detailed assessment

59 Arcles excluded
16 Incorrect study design or endpoint
7 Obstrucve CAD not defined
9 Abnormal CFR not prospecvely defined
9 Obstrucve CAD or recent MI included
18 Duplicate populaon

11 Studies included in the analysis
Figure 1. Flow diagram of included studies.
CAD indicates coronary artery disease; CFR, coronary flow reserve; and MI, myocardial infarction.
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population or enrollment period in articles published
by the same investigators, the article with the greatest
number of patients was used for the analysis.

Coronary Microvascular Dysfunction and Outcomes

The following information was extracted from each article: editorial information (lead author, publication year,
study size, and duration of follow-up), study population
information (number of patients for each study, percentage of female population, and age), risk factors,
such as smoking, hypertension, hyperlipidemia, and
diabetes mellitus, method of CFR determination, outcomes using raw data and expressed as crude event
rates, and adjusted time-to-event data, expressed as
hazard ratios (HRs) that dichotomized CFR as normal
or abnormal, if available. If results were presented for
>1 time point, the latest results were extracted. Studies
reporting the HR using CFR as a continuous variable
were not included. For studies that reported HRs for
subgroups, but not for the overall cohort, the HRs and
95% CIs for each subgroup were extracted. When relevant information was not included in the article, the
authors were contacted to obtain the data.

fixed-effects model and assumes that each sample
comes from a different population and that the effects in these populations may also differ. Estimates
of time-to-event data for mortality and MACE were
calculated using a random-effects model and were
expressed as HRs with 95% CIs. Statistical significance was set at P≤0.05 (2 tailed). Heterogeneity was
assessed by the I2 test. An I2 of <25% is considered
no statistical heterogeneity, 25% to 50% is considered as low statistical heterogeneity, 50% to 75% is
considered as medium statistical heterogeneity, and
>75% is considered as high statistical heterogeneity.
Planned sensitivity analyses included the leave-one-
out analysis as well as stratified analyses to assess
any potential differences in method of measurement
of CFR, for angiographic exclusion of obstructive
CAD compared with exclusion based on lack of ischemia on stress testing, and for different numerical
definitions of abnormal CFR. Because the number of
studies was <10 for both mortality and MACE end
points, a funnel plot assessment for publication bias
was not performed as the power of the tests is too
low to distinguish chance from real asymmetry.21

Outcomes

RESULTS

Data Extraction
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The primary outcome was all-cause mortality (or cardiac death or cardiovascular death if all-cause mortality
was not provided). The secondary outcome of interest
was MACE, including cardiac or cardiovascular death,
nonfatal myocardial infarction, coronary revascularization, or cardiac hospitalization.

Quality Assessment
Two investigators (M.A.G., D.L.B). assessed the risk of
bias using the Newcastle-Ottawa Scale20 for cohort
studies. A quality score was calculated on the basis
of 3 major components of cohort studies: selection
of study groups (0–4 points), comparability of study
groups (0–2 points), and ascertainment of the outcome
of interest (0–3 points). A higher score represents better methodologic quality. Disagreements in quality assessment were resolved by consensus.

Statistical Analysis
A meta-
analysis of summary statistics from each
article was performed using Comprehensive Meta-
Analysis 2.0 (Biostat, Inc) software. Estimates of
effect for both all-cause mortality (unless only cardiac or cardiovascular mortality was reported) and
MACE were calculated from crude event rates with a
random-effects model using inverse variance weighting, expressed as odds ratios (ORs) with 95% CIs,
and presented in forest plots. The random-effects
model provides more conservative results than a

Study Selection and Characteristics
The electronic search identified 3613 citations that
were screened by reviewing the title and abstract. A
total of 70 articles were assessed in full text and 11
studies were included in the meta-analysis (Figure 1).
For the calculation of ORs for mortality, 8 articles were
included in the meta-analysis.16,22–28 For the calculation
of ORs for MACE, 9 articles were included in the meta-
analysis.16,23,25–31Characteristics of included studies
are presented in Table 1.
The 8 articles that reported mortality enrolled 6631
patients, of whom 1970 had CMD (30%). CFR was
measured invasively in 2 studies, by PET in 3 studies,
and by transthoracic Doppler echocardiography of the
left anterior descending coronary artery in 3 studies.
Most patients were men (52%), and the mean age of
subjects ranged from 51 to 67 years.
The 9 articles that reported MACE enrolled 5189
patients, of whom 1447 had CMD (28%). CFR was
measured invasively in 1 study, by PET in 4 studies,
and by transthoracic Doppler echocardiography of the
left anterior descending coronary artery in 4 studies.
Most patients were women (52%), and the mean age
ranged from 51 to 67 years. Characteristics of patients
included in each study are presented in Table 2. We
evaluated each study using the Newcastle-
Ottawa
Scale quality assessment criteria for cohort studies.
Study quality is presented in Table S1. Of 9 possible
points, the median score was 8 (range, 8–9).
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Table 1. Characteristics of Included Studies

Author and Year
22

Method

Outcomes Extracted

Follow-up
(mean or
median), years

Abnormal
CFR
Cutoff

168

Intracoronary CFR
Doppler flow wire

Death

8.5

3.0

Herzog et al,23 2009

103

Adenosine
13N–ammonia PET

Cardiac death, nonfatal MI, cardiac
hospitalization, PCI/CABG

5.5

2.0

Cortigiani et al,29 2010

1660

Dipyridamole stress
TTE (LAD)

Nonfatal STEMI, NSTEMI, coronary
revascularization

1.6

2.0

Dipyridamole
rubidium-82 PET

Cardiac death, MI, PCI/CABG, cardiac
hospitalization

1.1

2.0

3548

Dipyridamole stress
TTE (LAD)

Death

1.6

2.0

Lowenstein et al,25 2014

651

Dobutamine or
dipyridamole stress
TTE (LAD)

Cardiovascular death, AMI, PCI/CABG

2.9

2.0

Murthy et al,16 2014

1218

Vasodilator rubidium-
82 PET

Cardiovascular death, AMI, PCI/CABG,
hospitalization for CHF

1.3

2.0

Dikic et al,31 2015

200

Adenosine stress TTE
(LAD)

Cardiovascular death, stroke, AMI, unstable
angina, PCI/CABG

1.2

2.0

Gan et al,26 2017

233

Adenosine stress TTE
(LAD)

Cardiovascular death, AMI, PCI/CABG

4.5

2.0

Lee et al,27 2018

631

Intracoronary CFR
guide wire

Cardiac death, vessel-oriented composite
outcomes (vessel-related death, MI, PCI)

5.1

2.0

Monroy-Gonzalez et al,28
2019

79

Vasodilator
13N–ammonia PET

All-cause mortality, hospitalization attributable
to heart failure, late revascularization

8

2.0

Marks et al,

2004

No. of
Subjects

Ziadi et al,30 2011
Cortigiani et al,24 2012

414

13N indicates nitrogen-13; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CFR, coronary flow reserve; CHF, congestive heart
failure; LAD, left anterior descending; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation MI; PCI, percutaneous coronary intervention; PET, positron
emission tomography; STEMI, ST-segment–elevation MI; and TTE, transthoracic echocardiogram.
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Quantitative Results
Of the 6631 patients included in the 8 studies reporting
mortality, there were a total of 305 deaths. There were
122 deaths in the 4661 patients without CMD (2.6%)
and 183 deaths in the 1970 patients with CMD (9.3%).
Of the 8 studies, 5 reported cardiac or cardiovascular
mortality only16,23,25–27 and the remaining 3 reported
all-cause mortality.22,24,28 The median follow-up ranged
from 19 months to 8.5 years. The OR for mortality in
patients with CMD compared with those without CMD
was 3.93 (95% CI, 2.91–5.30; P<0.001; I2=11.7%)
(Figure 2A). Three studies presented adjusted HRs for
mortality.16,23,24 The summary HR for mortality among
patients with CMD was 3.62 (95% CI, 2.45–5.35;
P<0.001; I2=17.2%) (Figure 2B).
A total of 5189 patients were included in the 9 studies that reported MACE, with 412 events reported.
There were 167 events in the 3742 patients with normal coronary microvascular function (4.5%) and 245
events in the 1447 patients with CMD (16.9%). The median follow-up ranged from 1 to 8 years. The OR for
MACE in patients with CMD compared with those with
normal coronary microvascular function was 5.16 (95%
CI, 2.81–9.47; P<0.001; I2=82.5%) (Figure 3A). Seven
studies presented adjusted HRs for MACE.23,25–27,29–
31
The summary HR for MACE among patients with

CMD was 4.42 (95% CI, 2.79–7.01; P<0.001; I2=75.2%)
(Figure 3B).

Sensitivity Analysis
Sensitivity analyses to assess the potential impact of
qualitative differences in study design and patient selection showed that exclusion of any single trial from
the analyses for mortality or MACE did not alter the
overall findings of the analysis and demonstrated that
no individual study had a disproportionate influence
on between-study heterogeneity. Likewise, the overall findings were not modified by an analysis stratified
by method of CFR measurement, use of angiography
to exclude obstructive CAD, or definition of abnormal
CFR (data not shown).

DISCUSSION
In this systematic review and meta-analysis of >5000
patients with suspected ischemia, nonobstructive epicardial CAD on coronary angiography, or absence of
myocardial ischemia on stress testing, ≈30% of patients, equally divided between men and women, had
abnormally reduced CFR diagnostic of CMD. In these
patients, we observed a nearly 4-fold higher mortality
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Table 2. Patient Characteristics
Study

Women,
%

Mean
Age, y

Diabetes Mellitus,
%

Hypertension,
%

Hyperlipidemia,
%

Smoking,
%

N/A

Marks 200422
Overall

65

52

21

85

N/A

Normal CFR

60

53

15

82

N/A

N/A

Abnormal CFR

73

51

33

88

N/A

N/A

31

60

18

60

59

42

55

63

19

63

46

25

39

64

29

68

69

64

Herzog 200923
Overall
Cortigiani 201029
Overall
Ziadi 201130
Overall
Cortigiani 201224
Overall

43

66

22

65

54

30

Normal CFR

44

64

19

64

52

30

Abnormal CFR

35

68

30

72

60

31

Lowenstein 201425
Overall

49

67

13

45

36

12

Normal CFR

49

66

11

44

37

10

Abnormal CFR

51

70

25

52

34

17

67

62

30

73

54

10

55

58

50

70

63

24

Murthy 201416
Overall
Dikic 201531
Overall
Gan 201726
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Overall

53

62

12

12

50

49

Normal CFR

43

62

11

13

48

46

Abnormal CFR

61

65

17

13

55

59

Lee 201827
Overall

29

61

29

59

64

18

Normal CFR

28

61

28

58

65

19

Abnormal CFR

33

64

31

61

60

17

Monroy-Gonzalez 201928
Overall

74

51

4

34

28

18

Normal CFR

71

51

4

36

27

9

Abnormal CFR

79

51

3

32

29

29

CFR indicates coronary flow reserve and N/A, not available.

and a 5-fold increase in MACE among individuals with
CMD compared with those with normal coronary microvascular function. CMD was not simply a marker for
other atherogenic risk factors as synthesis of covariate-
adjusted time-to-event data showed similar increases
in HRs for mortality and MACE. The increased risk associated with CMD was similar across 9 countries on 4
continents, different patient populations, and regardless
of the modality used to detect it, including invasive assessment during coronary angiography or noninvasive
testing with PET scans or Doppler echocardiography.
Although CMD is scarcely mentioned in the
American College of Cardiology/American Heart

Association guideline for stable ischemic heart
disease, with no recommendations provided for
diagnosis or treatment,32 it is not uncommon.
Approximately 4 million Americans receive a new diagnosis of angina annually.33,34 Up to 40% of these
patients are found to have nonobstructive CAD35
and 30% to 70% of such patients, equating to from
≈500 000 to 1 million Americans, have been demonstrated to have CMD.36 Unfortunately, stress testing
and computed tomography coronary angiography,
both of which are recommended in various guidelines37,38 for the evaluation of patients with symptoms consistent with myocardial ischemia and are
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Figure 2. Meta-analysis of mortality with and without coronary microvascular dysfunction (CMD).
A, Crude event rates. B, Covariate adjusted time-to-event data. Point estimates of the effect sizes are
shown for individual studies. Odds ratios or hazard ratios for individual studies are indicated by squares,
and 95% CIs are indicated by horizontal lines. Pooled estimates and their 95% CIs are represented by
diamonds. The sizes of the squares and the diamonds are proportional to the weight assigned to the
relative effect sizes. CFR indicates coronary flow reserve.

intended to diagnose obstructive epicardial CAD, fail
to detect CMD.
The only prior systematic review on the prognostic
value of CMD39 included studies of patients with hypertrophic obstructive cardiomyopathy, heart failure,
and aortic stenosis (type 2 CMD) who were excluded
in the present analysis that was limited to type 1 CMD.
Nevertheless, the findings were similar, with a relative
risk for cardiovascular events of 4.58 in patients with
CMD for studies measuring CFR using echocardiography and 2.44 for studies using PET.
The mechanisms by which CMD leads to adverse outcomes are poorly understood and are
likely multifactorial. Coronary blood flow, in healthy
individuals, is regulated at the level of the arterioles to meet myocardial oxygen demand. At rest,
myocardial oxygen extraction is near maximal and,
thus, adequate oxygen delivery to the myocardium
is dependent on coronary blood flow. The coronary

circulation coordinates the resistance in the microcirculation to maintain sufficient coronary blood flow
throughout the myocardium to prevent myocardial
ischemia in response to exercise or other stressful
stimuli. In patients with CMD, the microcirculation is
unable to adequately respond to stress, leading to
myocardial ischemia as a result of functional abnormalities, such as endothelial and smooth muscle cell
dysfunction, as well as structural abnormalities, including external compression and arteriolar rarefaction.40,41 These mechanisms likely contribute to the
increased mortality and MACE seen in patients with
CMD compared with patients with normal coronary
microvascular function. Furthermore, CMD is usually associated with mild diffuse atherosclerosis and
the combination of the 2 may have important clinical
implications.40 Recent evidence suggests that CMD
may also play a pivotal role in the development of
heart failure with preserved ejection fraction.42
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Figure 3. Meta-analysis of major adverse cardiac events (MACE) with and without coronary
microvascular dysfunction (CMD).
A, Crude event rates. B, Covariate-adjusted time-to-event data. Point estimates of the effect sizes are
shown for individual studies. Odds ratios or hazard ratios for individual studies are indicated by squares,
and 95% CIs are indicated by horizontal lines. Pooled estimates and their 95% CIs are represented by
diamonds. The sizes of the squares and the diamonds are proportional to the weight assigned to the
relative effect sizes. CFR indicates coronary flow reserve.

The precise number of patients who undergo testing for CMD is unknown but is likely to be extremely
low relative to the number of patients with ischemic
symptoms and nonobstructive CAD, given the belief
that ruling out obstructive CAD or myocardial ischemia
identifies low-
risk patients, the lack of widespread
availability of cardiac PET scanners and their myocardial perfusion tracers, lack of familiarity with the use
of Doppler echocardiography to interrogate the left
anterior descending coronary artery, and the negative
impact of invasive measurement of CFR on workflow
in catheterization laboratories. The significant underdiagnosis of CMD has likely dampened the incentive to
develop diagnostic algorithms and targeted therapies
and has been a major hurdle even for the validation of
existing therapeutics for modification of prognosis in

patients with CMD. Although some existing therapies
have been shown in small studies to reduce angina or
improve CFR, specific treatment options that improve
outcomes of patients with CMD beyond treatment of
established risk factors, such as hypertension, diabetes mellitus, hyperlipidemia, and smoking cessation,
are lacking.43

LIMITATIONS
There are several limitations of our study. First, CFR
is a continuous measure, but most studies dichotomize it using various cutoffs for normal and abnormal.
Second, caution is appropriate in interpreting the results of this meta-analysis because the results are
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based on data from observational studies. Although
our meta-analysis of covariate-adjusted HRs found
similar magnitudes of increased death and MACE as
with the unadjusted crude event rates, the possibility
of unequal distribution of important measured and
unmeasured prognostic variables remains. Third,
most of the included studies were performed at referral centers, which raises the possibility that the patients studied were not representative of the overall
population. A more precise estimate of the prognostic implications of CMD will require testing in unselected populations. Fourth, we accepted absence of
myocardial ischemia on stress testing as a surrogate
for the absence of obstructive CAD demonstrated by
coronary angiography. Although patients with CMD
do not uniformly have ischemia on stress testing because of the diffuse nature of CMD, some patients
do, and those patients would have been excluded
by our selection criteria. Fifth, we cannot exclude the
possibility that some patients with type 2 CMD were
included in the cohorts analyzed. Fifth, medical therapies, including β blockers, angiotensin-converting
enzyme inhibitors, aspirin, and statins, were inconsistently reported. Differential use of medical therapy
could potentially influence outcomes and confound
the results of the study. Sixth, we were unable to
perform sex-specific analysis of CMD because of the
lack of sex-specific frequency and outcomes data
in the included studies. Finally, we did not include
emerging technologies, such as magnetic resonance
imaging as, to our knowledge, there are no magnetic
resonance imaging studies of the population of interest that have prospectively defined abnormal CFR
and followed up patients for adverse outcomes.

CONCLUSIONS
This systematic review and meta-analysis of aggregate
data suggests that patients with isolated CMD, as demonstrated by abnormally reduced CFR, measured invasively or noninvasively, are at substantially increased
risk of mortality and MACE when compared with those
without CMD. These results support the need to integrate the totality of the coronary circulation, both macrovascular and microvascular, when conceptualizing
the pathophysiological characteristics, treatment, and
prognosis of patients with symptoms of ischemic heart
disease. The recently reported CorMicA (Coronary
Microvascular Angina) study demonstrated an improvement in quality of life among angina patients without obstructive CAD who underwent vasoreactivity testing and
were treated on the basis of those results compared with
standard care.44 Furthermore, multiple knowledge gaps
exist in our understanding of CMD, which require an intensified research agenda to establish evidence-based
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approaches to the diagnostic evaluation and management of patients with CMD.45
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Supplemental Methods

Systematic review search strategy

Ovid Medline
08/17/17
1,184 results
Updated search = 168 results after limit to yr= “2017-Current” on 12/26/18
Updated search = 39 results after limit to yr="2019 -Current" on 04/18/19
Coronary flow reserve.mp. OR Coronary flow reserves.mp. OR coronary flow velocity reserve.mp. OR
coronary flow velocity reserves.mp. OR coronary flow reserve velocity.mp. OR myocardial flow
reserve.mp. OR CFVR.mp. OR (("Myocardial blood flow" adj8 (stress OR hyperemia)) AND rest).mp.

AND
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(Measure*.mp. OR Quantif*.mp. OR heart output determination.mp. OR cardiac output
determination.mp. OR Exp diagnostic imaging/ OR Diagnostic imaging.mp. OR Diagnostic imaging.fs. OR
((intracardiac OR EKG OR cardiac) adj2 imaging).mp. OR angiocardiograph*.mp. OR angio
cardiography.mp. oR angiocardiogram.mp. OR cardioangiography.mp. OR heart angiography.mp. OR
heart arteriography.mp. OR scintiangiocardiography.mp. OR cineangiocardiography.mp. OR (coronary
adj1 (angiograph* OR arteriograp* OR arteriogram)).mp. OR Exp echocardiography/ OR
echocardiograph*.mp. OR echocardiogram.mp. OR cardiac echography.mp. OR cardiac scanning.mp. OR
cardial echography.mp. OR cardioechography.mp. OR echo cardiogram.mp. OR echo cardiography.mp.
OR echocardiogram.mp. OR heart echo sounding.mp. OR heart echography.mp. OR heart scanning.mp.
OR myocardium scanning.mp. OR myocardial perfusion imaging.mp. OR myocardial scintigraphy.mp. OR
radionuclide ventriculography.mp. OR ("myocardial perfusion" adj7 assess*).mp. OR ("myocardial blood
flow" adj7 assess*).mp. OR Exp Thermodilution/ OR thermodilution.mp. OR thermal dilution.mp. OR
adenosine.mp. OR dipyridamole.mp. OR Dipyridamol.mp. OR dipyridimole.mp. oR dipiridamole.mp. OR
(Doppler adj1 tte).mp. OR ((transthoracic OR flowmetry OR method OR system OR Technique) adj1
doppler).mp. OR vasodilator*.mp. OR nuclear stress test.mp. OR Exp Positron-Emission Tomography/
OR positron emission tomography.mp. OR (PET adj2 scan*).mp. OR positron emission tomographic
scan.mp. OR positron emission tomographic scanning.mp. OR positron tomography.mp. OR positronemission tomography.mp. OR magnetic resonance.mp. OR mri.mp. OR Exp ultrasonography/ OR
ultrasound.mp.)

AND
(Follow-up.mp. OR Follow*.mp. OR Predictor*.mp. OR Outcome*.mp. OR Exp death/ OR Death.mp. OR
Exp myocardial infarction/ OR ((myocardi* OR cardiac OR heart) adj1 infarct*).mp. OR (cardiovascular
adj1 stroke*).mp. OR (heart adj1 attack*).mp. OR Exp hospitalization/ OR hospitalization.mp. OR
((hospital OR patient*) adj2 admi*).mp. OR ((hospital or patient*) adj2 readmi*).mp. OR major adverse

cardiovascular events.mp. OR major adverse cardiovascular event.mp. OR MACE.mp. OR MACEs.mp. OR
Exp heart failure/ OR ((cardiac OR heart OR myocardial) adj1 failure).mp. OR ((prospective OR
longitudinal) adj1 stud*).mp. OR years after.mp.)
Embase
08/18/17
2,401 results
Updated search = 390 results after limit to [18-8-2017]/sd NOT [27-12-2018]/sd on 12/26/18
Updated search = 104 results after limit to [26-12-2018]/sd NOT [19-4-2019]/sd on 04/18/19
(‘coronary flow reserve’/exp OR ‘Coronary flow reserve’:ti,ab,kw,de OR ‘Coronary flow
reserves’:ti,ab,kw,de OR ‘coronary flow velocity reserve’:ti,ab,kw,de OR ‘coronary flow velocity
reserves’:ti,ab,kw,de OR ‘coronary flow reserve velocity’:ti,ab,kw,de OR ‘myocardial flow
reserve’:ti,ab,kw,de OR ‘CFVR’:ti,ab,kw,de OR ((‘Myocardial blood flow’ near/8 (stress OR hyperemia))
AND rest):ti,ab,kw,de)

AND
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(‘cardiac imaging’/exp OR ‘angiocardiography’/exp OR ‘echocardiography’/exp OR ‘ultrasound’/exp OR
‘doppler flowmetry’/exp OR ‘positron emission tomography’/exp OR Measure*:ti,ab,kw,de OR
Quantif*:ti,ab,kw,de OR ‘heart output determination’:ti,ab,kw,de OR ‘cardiac output
determination’:ti,ab,kw,de OR ‘diagnostic imaging’/exp OR ‘Diagnostic imaging’:ti,ab,kw,de OR
((intracardiac OR EKG OR cardiac) near/2 imaging):ti,ab,kw,de OR ‘angiocardiograph*’:ti,ab,kw,de OR
‘angio cardiography’:ti,ab,kw,de oR ‘angiocardiogram’:ti,ab,kw,de OR ‘cardioangiography’:ti,ab,kw,de
OR ‘heart angiography’:ti,ab,kw,de OR ‘heart arteriography’:ti,ab,kw,de OR
‘scintiangiocardiography’:ti,ab,kw,de OR ‘cineangiocardiography’:ti,ab,kw,de OR (coronary near/1
(angiograph* OR arteriograp* OR arteriogram)):ti,ab,kw,de OR echocardiograph*:ti,ab,kw,de OR
echocardiogram:ti,ab,kw,de OR ‘cardiac echography’:ti,ab,kw,de OR ‘cardiac scanning’:ti,ab,kw,de OR
‘cardial echography’:ti,ab,kw,de OR ‘cardioechography’:ti,ab,kw,de OR ‘echo cardiogram’:ti,ab,kw,de OR
‘echo cardiography’:ti,ab,kw,de OR ‘echocardiogram’:ti,ab,kw,de OR ‘heart echo sounding’:ti,ab,kw,de
OR ‘heart echography’:ti,ab,kw,de OR ‘heart scanning’:ti,ab,kw,de OR ‘myocardium
scanning’:ti,ab,kw,de OR ‘myocardial perfusion imaging’:ti,ab,kw,de OR ‘myocardial
scintigraphy’:ti,ab,kw,de OR ‘radionuclide ventriculography’:ti,ab,kw,de OR (‘myocardial perfusion’
near/7 assess*):ti,ab,kw,de OR (‘myocardial blood flow’ near/7 assess*):ti,ab,kw,de OR
‘Thermodilution’/exp OR ‘thermodilution’:ti,ab,kw,de OR ‘thermal dilution’:ti,ab,kw,de OR
‘adenosine’:ti,ab,kw,de OR ‘dipyridamole’:ti,ab,kw,de OR ‘Dipyridamol’:ti,ab,kw,de OR
‘dipyridimole’:ti,ab,kw,de oR ‘dipiridamole’:ti,ab,kw,de OR (Doppler near/1 tte):ti,ab,kw,de OR
((transthoracic OR flowmetry OR method OR system OR Technique) near/1 doppler):ti,ab,kw,de OR
vasodilator*:ti,ab,kw,de OR ‘nuclear stress test’:ti,ab,kw,de OR ‘positron emission
tomography’:ti,ab,kw,de OR (PET near/2 scan*):ti,ab,kw,de OR ‘positron emission tomographic
scan’:ti,ab,kw,de OR ‘positron emission tomographic scanning’:ti,ab,kw,de OR ‘positron
tomography’:ti,ab,kw,de OR ‘positron-emission tomography’:ti,ab,kw,de OR ‘magnetic
resonance’:ti,ab,kw,de OR ‘mri’:ti,ab,kw,de OR ‘ultrasound’:ti,ab,kw,de)

AND
(‘follow up’/exp OR ‘outcome assessment’/exp OR ‘patient assessment’/exp OR ‘heart infarction’/exp

OR ‘major adverse cardiac event’/exp OR ‘Follow-up’:ti,ab,kw,de OR ‘Follow*’:ti,ab,kw OR
‘Predictor*’:ti,ab,kw,de OR ‘Outcome*’:ti,ab,kw,de OR ‘death’/exp OR ‘Death’:ti,ab,kw,de OR
((myocardi* OR cardiac OR heart) near/1 infarct*):ti,ab,kw,de OR (cardiovascular near/1
stroke*):ti,ab,kw,de OR (heart near/1 attack*):ti,ab,kw,de OR ‘hospitalization’/exp OR
‘hospitalization’:ti,ab,kw,de OR ((hospital OR patient*) near/2 admi*):ti,ab,kw,de OR ((hospital or
patient*) near/2 readmi*):ti,ab,kw,de OR ‘major adverse cardiovascular events’:ti,ab,kw,de OR ‘major
adverse cardiovascular event’:ti,ab,kw,de OR ‘MACE’:ti,ab,kw,de OR ‘MACEs’:ti,ab,kw,de OR ‘heart
failure’/exp OR ((cardiac OR heart OR myocardial) near/1 failure):ti,ab,kw,de OR ((prospective OR
longitudinal) near/1 stud*):ti,ab,kw,de OR ‘years after’:ti,ab,kw,de OR 'major adverse cardiac and
cerebrovascular events':ti,ab,kw OR 'major adverse cardiac and cerebrovascular event':ti,ab,kw OR
'macce':ti,ab,kw OR ‘macces’:ti,ab,kw)

Cochrane Library
08/18/17
Cochrane Database of Systematic Reviews– 0 results
Cochrane Central Register of Controlled Trials – 170 results
Database of Abstracts of Reviews of Effect – 0 results
Updated search for Cochrane Central Register of Controlled Trials (Central) = 32 results after limit to
“Year first published 2017 to 2018” on 12/26/18
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Updated search for Cochrane Database of Systematic Reviews = 0 results after limit to “Year first
published 2017 to 2018” on 12/26/18
Updated search for Cochrane Central Register of Controlled Trials (Central) = 43 results after limit to
Date added to CENTRAL trials database 26/12/2018 to 18/04/2019 on 12/26/18
Updated search for Cochrane Database of Systematic Reviews = 0 results after limit to “Year first
published 2017 to 2018” on 12/26/18
(“Coronary flow reserve”:ti,ab,kw OR “Coronary flow reserves”:ti,ab,kw OR “coronary flow velocity
reserve”:ti,ab,kw OR “coronary flow velocity reserves”:ti,ab,kw
OR “coronary flow reserve
velocity”:ti,ab,kw OR “myocardial flow reserve”:ti,ab,kw OR CFVR:ti,ab,kw OR ((“Myocardial blood
flow” near/8 (stress OR hyperemia)) AND rest):ti,ab,kw)

AND
(Measure*:ti,ab,kw OR Quantif*:ti,ab,kw OR “heart output determination”:ti,ab,kw OR “cardiac output
determination”:ti,ab,kw OR [mh “diagnostic imaging”] OR “Diagnostic imaging”:ti,ab,kw OR [mh
“Diagnostic imaging”/ae] OR ((intracardiac OR EKG OR cardiac) near/2 imaging):ti,ab,kw OR
angiocardiograph*:ti,ab,kw OR “angio cardiography”:ti,ab,kw OR “angiocardiogram”:ti,ab,kw OR
“cardioangiography”:ti,ab,kw OR “heart angiography”:ti,ab,kw OR “heart arteriography”:ti,ab,kw OR
“scintiangiocardiography”:ti,ab,kw OR “cineangiocardiography”:ti,ab,kw OR (coronary near/1
(angiograph* OR arteriograp* OR arteriogram)):ti,ab,kw OR [mh echocardiography] OR
echocardiograph*:ti,ab,kw OR “echocardiogram”:ti,ab,kw OR “cardiac echography”:ti,ab,kw OR “cardiac
scanning”:ti,ab,kw OR “cardial echography”:ti,ab,kw OR “cardioechography”:ti,ab,kw OR “echo
cardiogram”:ti,ab,kw OR “echo cardiography”:ti,ab,kw OR “echocardiogram”:ti,ab,kw OR “heart echo

sounding”:ti,ab,kw OR “heart echography”:ti,ab,kw OR “heart scanning”:ti,ab,kw OR “myocardium
scanning”:ti,ab,kw OR “myocardial perfusion imaging”:ti,ab,kw OR “myocardial scintigraphy”:ti,ab,kw
OR “radionuclide ventriculography”:ti,ab,kw OR (“myocardial perfusion” near/7 assess*):ti,ab,kw OR
(“myocardial blood flow” near/7 assess*):ti,ab,kw OR [mh Thermodilution] OR
“thermodilution”:ti,ab,kw OR “thermal dilution”:ti,ab,kw OR “adenosine”:ti,ab,kw OR
“dipyridamole”:ti,ab,kw OR “Dipyridamol”:ti,ab,kw OR “dipyridimole”:ti,ab,kw OR
“dipiridamole”:ti,ab,kw OR (Doppler near/1 tte):ti,ab,kw OR ((transthoracic OR flowmetry OR method
OR system OR Technique) near/1 doppler):ti,ab,kw OR vasodilator*:ti,ab,kw OR “nuclear stress
test”:ti,ab,kw OR [mh “Positron-Emission Tomography”] OR “positron emission tomography”:ti,ab,kw
OR (PET near/2 scan*):ti,ab,kw OR “positron emission tomographic scan”:ti,ab,kw OR “positron emission
tomographic scanning”:ti,ab,kw OR “positron tomography”:ti,ab,kw OR “positron-emission
tomography”:ti,ab,kw OR “magnetic resonance”:ti,ab,kw OR “mri”:ti,ab,kw OR [mh ultrasonography] OR
ultrasound:ti,ab,kw)

AND
(Follow-up:ti,ab,kw OR Follow*:ti,ab,kw OR Predictor*:ti,ab,kw OR Outcome*:ti,ab,kw OR [mh death]
OR Death:ti,ab,kw OR [mh “myocardial infarction”] OR ((myocardi* OR cardiac OR heart) near/1
infarct*):ti,ab,kw OR (cardiovascular near/1 stroke*):ti,ab,kw OR (heart near/1 attack*):ti,ab,kw OR [mh
hospitalization] OR hospitalization:ti,ab,kw OR ((hospital OR patient*) near/2 admi*):ti,ab,kw OR
((hospital or patient*) near/2 readmi*):ti,ab,kw OR “major adverse cardiovascular events”:ti,ab,kw OR
“major adverse cardiovascular event”:ti,ab,kw OR MACE:ti,ab,kw OR MACEs:ti,ab,kw OR [mh “heart
failure”] OR ((cardiac OR heart OR myocardial) near/1 failure):ti,ab,kw OR ((prospective OR longitudinal)
near/1 stud*):ti,ab,kw OR “years after”:ti,ab,kw)
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Scopus
08/18/17
1,756 results
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Table S1. Results of quality appraisal using the Newcastle-Ottawa scale.
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